HEALTH TECHNOLOGY ASSESSMENT (HTA) FOR ORPHAN DRUGS IN COST-EFFECTIVENESS (CE) MARKETS: CURRENT DEVELOPMENT AND FUTURE TRENDS

被引：2
|
作者：
Zhang, A. [1 ]
Weisse, S. [1 ]
Chen, X. [1 ]
机构：
[1] Pope Woodhead, St Ives, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1464
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY147
引用
收藏
页码：A601 / A601
页数：1
相关论文
共 50 条
  • [1] Analysis of Health Technology Assessment (HTA) Procedures and Outcomes for Orphan Drugs
    Warttig, S.
    D'Souza, V
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S334 - S335
  • [2] THE INFLUENCE OF COST-EFFECTIVENESS ISSUES OF THE APPRAISED ORPHAN DRUGS ON RECOMMENDATIONS OF AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AHTAPOL)
    Ofierska-Sujkowska, G.
    Jagodzinska-Kalinowska, K.
    Matusewicz, W.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A21 - A21
  • [3] Cost-Effectiveness Assessment of Orphan Drugs A Scientific and Political Conundrum
    Simoens, Steven
    Picavet, Eline
    Dooms, Marc
    Cassiman, David
    Morel, Thomas
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2013, 11 (01) : 1 - 3
  • [4] AWARENESS AND CONSIDERATION OF CONFIDENTIAL LISTING AGREEMENTS IN COST-EFFECTIVENESS EVALUATION BY HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES
    Ouellet, N.
    Bilodeau, V
    [J]. VALUE IN HEALTH, 2021, 24 : S92 - S92
  • [5] The Development of Health Technology Assessment in Asia: Current Status and Future Trends
    Liu, Gordon
    Wu, Eric Q.
    Ahn, Jeonghoon
    Kamae, Isao
    Xie, Jipan
    Yang, Hongbo
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2020, 21 : 39 - 44
  • [6] Health Technology Assessment (HTA) in Peru: current situation and future challenges
    Reyes, Nora
    Huaman, Karen
    Neyra-Rivera, Carlos D.
    Acevedo-Flores, Jessica
    Perez-Acuna, Katherine
    Morales-Barrenechea, Javier
    Gutierrez-Aguado, Alfonso
    Gutierrez, Ericson L.
    [J]. REVISTA DEL CUERPO MEDICO DEL HOSPITAL NACIONAL ALMANZOR AGUINAGA ASENJO, 2022, 15
  • [7] Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs
    Chambers, James D.
    Silver, Madison C.
    Berklein, Flora C.
    Cohen, Joshua T.
    Neumann, Peter J.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (09) : 2629 - 2636
  • [8] HOW WIDE RANGING IS THE IMPLEMENTATION OF HTA AND COST-EFFECTIVENESS ASSESSMENT (CEA) IN MAJOR HEALTHCARE MARKETS
    Ricci, M.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S376 - S376
  • [9] Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs
    James D. Chambers
    Madison C. Silver
    Flora C. Berklein
    Joshua T. Cohen
    Peter J. Neumann
    [J]. Journal of General Internal Medicine, 2020, 35 : 2629 - 2636
  • [10] EVIDENCE GAPS IN EVALUATING COMPARATIVE EFFECTIVENESS, SAFETY, AND COST-EFFECTIVENESS OF BIOLOGICS IN HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS FOR THE TREATMENT OF SEVERE ASTHMA
    Zhang, L.
    Musat, M.
    Gurjar, K.
    Vu, B. K.
    Islam, S.
    Thakur, D.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S271 - S271
12345